Objectives: We conducted a prospective randomized study to evaluate the efficacy of two newly developed spinal orthoses in patients with vertebral fractures.
Design: We conducted a prospective, randomized, cross-over study to evaluate the efficacy of two newly developed spinal orthoses in patients with osteoporotic vertebral fractures. Measurements include trunk muscle strength, angle of kyphosis, body height, body sway, and parameters of quality-of-life such as pain, well-being, and limitations of daily living.
The objective of exercise in the treatment of osteoporosis is to improve axial stability through improvement of muscle strength. Therefore, a back extension exercise program specific to one's musculoskeletal competence and pain can be performed in a sitting position and later advanced to the prone position. When fragility is resolved, back extension is performed against resistance applied to the upper back.
View Article and Find Full Text PDFSince the approval of teriparatide for clinical application, a number of iliac crest studies have focused on increases in bone volume or changes in structural parameters with microCT and numerical changes in histomorphometry. This investigation is based on individual histopathological observations related to early and late effects of teriparatide treatment in humans. A total of 44 (18 paired) iliac crest biopsies (ICB) from 41 patients receiving teriparatide (10 months +/- 6 months) following bisphosphonate (BP) treatment were investigated for hematopoietic changes, bone turnover, and description of microarchitectural changes using histology and selective microCT.
View Article and Find Full Text PDFAlthough vitamin D supplementation is a fundamental part of osteoporosis treatment, many patients do not regularly take adequate amounts. A once-weekly (OW) alendronate (ALN) preparation that includes 2800 IU of vitamin D3 in a single combination tablet (ALN+D2800) is available for treating patients and ensuring intake of vitamin D that is consistent with existing guidelines. This randomized, double-blind study extension was conducted to evaluate the safety and tolerability of ALN+D2800 and ALN+D2800 plus an additional 2800 IU vitamin D3 single tablet supplement (ALN+D5600) administered for 24 weeks in men and postmenopausal women with osteoporosis previously treated OW for 15 weeks with either ALN or ALN+D2800.
View Article and Find Full Text PDFObjective: Recombinant teriparatide, a bone anabolic agent, is given to treatment-naïve and pre-treated patients with severe osteoporosis, but few data exist comparing the response to teriparatide in these groups. EUROFORS (the EUROpean study of FORSteo‡) enrolled postmenopausal women with established osteoporosis who were either treatment-naïve or had prior antiresorptive (AR) treatment with or without documented inadequate clinical response. The objective of the secondary analysis described here was to evaluate the interim bone mineral density (BMD) response in these groups after one year of open-label teriparatide therapy.
View Article and Find Full Text PDFAlthough Paget's disease of bone (PDB) is the second most common metabolic bone disease, to our knowledge, there is only one quantitative analysis on the histological and especially on the histomorphometric level. Therefore, the aim of this study was to analyze, on the basis of the Hamburg Bone Register, PBD in terms of incidence, skeletal distribution, malignant transformation, and histological and histomorphometric characteristics. Bone biopsies and patient files of 754 cases with histologically proven PDB were reviewed in a retrospective study.
View Article and Find Full Text PDFAccording to the recently published BoneEVA study, 7.8 million Germans (6.5 million women) are affected by osteoporosis.
View Article and Find Full Text PDFObjectives: Patient preference strongly influences long-term medication use in chronic diseases such as postmenopausal osteoporosis.
Methods: This 6-month, open-label, crossover, international study randomized 350 women with postmenopausal osteoporosis to monthly oral ibandronate 150mg for 3months followed by weekly alendronate 70mg for 12weeks, or vice versa.
Results: Of patients expressing a preference (93.
Med Klin (Munich)
June 2006
During the last 5 years several randomized, prospective, placebo-controlled clinical trials have documented that a supplementation with vitamin D (400-1,200 IU per day) together with calcium (800-1,500 mg per day) may reduce the risk of falls and fall-related fractures in the elderly. This is especially the case in elderly women >or= 65 years of age with a serum 25-hydroxy-vitamin-D(3) level < 50 nmol/l. Based on the results of a recently published meta-analysis involving more than 10,000 participants, the grade of evidence according to the Oxford Centre of Evidence-based Medicine is Ia with respect to the primary prevention of falls in the elderly population.
View Article and Find Full Text PDFWomen with established osteoporosis are at high risk to sustain additional vertebral fractures. Treatment may affect the predictive power of bone densitometry and biochemical techniques. There are few prospective studies comparing fracture prediction by dual-energy X-ray absorptiometry (DXA) and other techniques in treated women with established osteoporosis.
View Article and Find Full Text PDFMeasures of musculoskeletal rehabilitation play an integral part in the management of patients with increased fracture risk because of osteoporosis or extraskeletal risk factors. This article delineates current scientific evidence concerning nonpharmacologic approaches that are used in conjunction with pharmacotherapy for prevention and management of osteoporosis. Fractures caused by osteoporotic fragility may be prevented with multidisciplinary intervention programs, including education, environmental modifications, aids, and implementation of individually tailored exercise programs, which are proved to reduce falls and fall-related injuries.
View Article and Find Full Text PDFObjective: One fourth of women > or =50 yrs of age in the general population have one or more vertebral fractures. The orthotic treatment modality in the management of vertebral fractures caused by osteoporosis remains subjective because no objective data from clinical trials are available. The objective of this research was to evaluate the efficacy of a newly developed spinal orthosis in patients with osteoporotic vertebral fractures.
View Article and Find Full Text PDF